CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors

PURPOSE: In prostate cancer, inactivating CDK12 mutations lead to gene fusion–induced neoantigens and possibly sensitivity to immunotherapy. We aimed to clinically, pathologically, and molecularly characterize CDK12-aberrant prostate cancers. METHODS: We conducted a retrospective multicenter study t...

全面介紹

Na minha lista:
書目詳細資料
發表在:JCO Precis Oncol
Main Authors: Antonarakis, Emmanuel S., Isaacsson Velho, Pedro, Fu, Wei, Wang, Hao, Agarwal, Neeraj, Santos, Victor Sacristan, Maughan, Benjamin L., Pili, Roberto, Adra, Nabil, Sternberg, Cora N., Vlachostergios, Panagiotis J., Tagawa, Scott T., Bryce, Alan H., McNatty, Andrea L., Reichert, Zachery R., Dreicer, Robert, Sartor, Oliver, Lotan, Tamara L., Hussain, Maha
格式: Artigo
語言:Inglês
出版: American Society of Clinical Oncology 2020
主題:
Original Reports
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7252221/
https://ncbi.nlm.nih.gov/pubmed/32462107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.19.00399
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍